Targeting pancreatic cancer with specialized platinum drugs.
Official title: Precision medicine for pancreatic cancer. Biomarker-guided drug delivery of platinum to tumors
Funded at Bioplatinum Technologies, LLC · NIH-10919357 · Data updated 2026-11-12
This study is looking at new cancer drugs made with platinum to help treat pancreatic cancer, and it aims to find out how certain markers in tumors can help these drugs work better for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bioplatinum Technologies, LLC NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | August 6, 2024 |
| Project end | August 5, 2025 |
| Funding year | 2024 |
| Award (this year) | $338,828 |
| NIH project number | 1R41CA287830-01A1 |
| Project ID | NIH-10919357 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic cancer who have tumors expressing high levels of specific biomarkers related to drug sensitivity.
✕Less likely to help
Patients with pancreatic cancer who do not express the targeted biomarkers or have advanced disease stages may not benefit from this research.
What this research studies
This research focuses on developing new platinum-based anticancer drugs specifically for pancreatic cancer treatment. It aims to understand how the tumor's extracellular matrix and specific biomarkers can enhance the delivery and effectiveness of these drugs. By identifying patients whose tumors express certain biomarkers, the research seeks to tailor treatments that could overcome drug resistance and improve outcomes. The approach combines advanced drug delivery techniques with biomarker analysis to optimize therapy for pancreatic cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Other research has shown promise in using biomarker-guided therapies for cancer treatment, suggesting that this approach could be effective, although the specific application to pancreatic cancer with these platinum drugs is relatively novel.
Where this research is happening
-
Bioplatinum Technologies, LLC
Richmond, United States Active
Researchers
- Principal investigator: Farrell, Nicholas Patrick — Bioplatinum Technologies, LLC
- Study coordinator: Farrell, Nicholas Patrick
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.